Table 1.
Clinicopathologic characteristics of the patients, initial gastric cancer stage, and treatments
| Characteristic | No. (%) (n=790) |
|---|---|
| Age, mean±SD (yr) | 57.18±12.53 |
| Sex | |
| Male | 521 (65.9) |
| Female | 269 (34.1) |
| Serosa invasion | |
| Negative | 355 (44.9) |
| Positive | 435 (55.1) |
| LN metastasis | |
| Negative | 64 (8.1) |
| Positive | 726 (91.9) |
| TNM stage | |
| II | 188 (23.8) |
| III | 602 (76.2) |
| Lauren classification | |
| Intestinal | 293 (37.1) |
| Diffuse/Mixed | 497 (62.9) |
| Tumor location | |
| UB/Whole | 133 (16.8) |
| MB/LB | 657 (83.2) |
| MSI/MMR | |
| MSS/pMMR | 726 (91.9) |
| MSI-H/dMMR | 64 (8.1) |
| Adjuvant CTxa) | |
| No | 214 (27.3) |
| Yes | 570 (72.7) |
| Interval to recurrence (yr) | |
| < 1 | 322 (40.8) |
| ≥ 1, < 2 | 237 (30.0) |
| ≥ 2 | 231 (29.2) |
| Type of recurrence | |
| Locoregional | 132 (16.7) |
| Hematogenous | 154 (19.5) |
| Peritoneum | 336 (42.5) |
| Any combination | 142 (18.0) |
| Krukenberg only | 26 (3.3) |
| CTx after recurrencea) | |
| No | 265 (35.1) |
| Yes | 489 (64.9) |
LN, lymph node; UB, upper body; MB, mid-body; LB, lower body; MSI, microsatellite instability; MMR, mismatch repair; MSS, microsatellite stable; pMMR, proficient mismatch repair; MSI-H, microsatellite instability high; dMMR, deficient mismatch repair; CTx, chemotherapy.
a)
Information was incomplete in some patients because of transfer to other hospital, loss of follow-up, and unclear medical records.